Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 191-200 of 639 results
Medicine, 2023 • December 1, 2023
The study aimed to analyze the potential molecular mechanisms of action of VJJ in the treatment of SCI, using network pharmacology and molecular docking techniques. Key findings include the identifica...
KEY FINDING: Identified 56 active ingredients of VJJ, primarily iridoids, which are believed to be the main components responsible for its therapeutic effects.
Frontiers in Pharmacology, 2023 • December 11, 2023
This study investigates the phase-specific effects of progesterone on neuropathic pain in mice with sciatic nerve injury, focusing on the roles of P450c17 and 5α-reductase. The research reveals that p...
KEY FINDING: Intrathecal progesterone administration during the induction phase of chronic pain enhanced mechanical allodynia development and spinal GFAP expression, an effect inhibited by a P450c17 inhibitor.
Front. Pain Res., 2023 • December 21, 2023
This study explored the self-reported effects of cannabis and cannabinoids on neuropathic pain and pain medication use in individuals with spinal cord injury (SCI). The findings suggest that cannabis ...
KEY FINDING: 87.9% of participants reported that cannabis reduced their neuropathic pain intensity by more than 30%.
AMB Express, 2024 • January 31, 2024
The study aimed to improve the characteristics and efficiency of chondroitinase ABCI (chABCI) by immobilizing it on hydroxyapatite particles (HAPs). The results demonstrated that immobilized chABCI on...
KEY FINDING: Hydroxyapatite enhances the shelf life of chondroitinase when used as a carrier matrix.
Medicine, 2024 • February 1, 2024
This review uses network pharmacology and molecular docking to investigate the mechanisms of Zhenbao Pill (ZBP) in treating spinal cord injury (SCI). The study identifies key ingredients, targets, and...
KEY FINDING: ZBP contains 391 active ingredients and targets 836 proteins, with 1557 genes related to spinal cord injury.
Neurotrauma Reports, 2024 • January 1, 2024
This study systematically reviewed and meta-analyzed the safety and efficacy of riluzole in patients with traumatic spinal cord injury (SCI). The meta-analyses included five studies and found that ril...
KEY FINDING: Riluzole showed a trend toward increased ASIA motor scores at 3 and 6 months post-injury, but not statistically significant.
International Neurourology Journal, 2024 • February 29, 2024
This review article explores the pathophysiology of overactive bladder (OAB), highlighting the neurogenic, myogenic, and urothelial mechanisms involved in its development. It discusses how afferent si...
KEY FINDING: OAB pathophysiology involves neurogenic, myogenic, and urothelial mechanisms, with afferent noises triggering urgency-related detrusor contractions.
Frontiers in Cellular Neuroscience, 2024 • March 5, 2024
This study demonstrates that lasmiditan, a 5-HT1FR agonist, induces mitochondrial biogenesis (MB) in brain microvascular endothelial cells (mBMEC). Lasmiditan enhances endothelial cell function by inc...
KEY FINDING: Lasmiditan treatment increased the maximal oxygen consumption rate, mitochondrial proteins and mitochondrial density in mBMEC, indicative of MB induction.
Ultrasound Med Biol, 2024 • June 1, 2024
This study investigated the feasibility of using ultrasound to burst PLA microbubbles for targeted drug delivery to spinal cord injuries. The researchers optimized ultrasound parameters, evaluated mic...
KEY FINDING: PLA microbubbles can be successfully imaged and burst in a spinal cord injury model using clinical ultrasound.
Biomedicines, 2024 • March 8, 2024
The study synthesized MSR405, a lipophilic derivative of Radix Isatidis, and investigated its therapeutic effect on spinal cord injury (SCI) model rats. MSR405 was found to improve motor function and ...
KEY FINDING: MSR405 treatment significantly improved the motor function of SCI rats, as measured by BBB scores and footprint analysis.